Georgia Read discusses how the ophthalmology market is experiencing a remarkable surge, driven by a combination of technological advancements, an aging population, and increasing prevalence of ocular diseases. Read more below: https://lnkd.in/eAMFNMJN #ophthalmology #eyedisorders #eyetreatment
Mantell Associates
Executive Search Services
City of London, England 81,407 followers
Multidiscipline Global Life Science and Pharmaceutical Headhunting Firm.
About us
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
External link for Mantell Associates
- Industry
- Executive Search Services
- Company size
- 51-200 employees
- Headquarters
- City of London, England
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals, and Highly Potent Active Pharmaceutical Ingredients
Locations
-
Primary
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Employees at Mantell Associates
Updates
-
A big thank you to Siobhan McLoughlin as she celebrates 4 years at Mantell Associates! Joining the company in August 2020 during COVID-19, Siobhan was our first non-sales hire and now longest-serving employee, working alongside our CEO Alessandro Mantell. Siobhan is our Director of Marketing, and over the past 4 years has built the MA brand and following, transformed our internal ways of working, and helped the firm grow, adapt and change. Congratulations and thank you for all your hard work! #workanniversary #leadership #recruitmentmarketing
-
-
We are proud to have reached our next milestone of over 80,000 followers on LinkedIn! Thank you to everyone who has followed MA’s journey since 2019. This milestone is a testament to our passion and dedication in aiding the growth of the Pharmaceutical and Life Science space. #followers #milestone #recruitment
-
-
SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving both the small molecule and cell & gene therapy industry, and Rznomics Inc., a South Korea-based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, have signed a memorandum of understanding (MOU) for a contract development and manufacturing partnership. Read more below: https://lnkd.in/e8gVh_KU #genetherapy #cdmo #smallmolecule
SK Pharmteco, Rznomics Sign MOU for Development & Manufacturing Pact
contractpharma.com
-
Throwback to our last Directors Lunch Club! The team enjoyed an afternoon out in London, starting with drinks at Wagtail Rooftop followed by lunch at The Maine in Mayfair. Our monthly Lunch Club is designed to celebrate success as a team - well done to everyone who qualified! #recruitmentlondon #recruitmentincentives #incentives
-
-
Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai Co., Ltd., which has signed a $1.5 billion biobucks pact with Seed Therapeutics for undisclosed neurodegeneration and oncology targets. Read more below: https://lnkd.in/e_bcM9tN #oncology #neurology #biotech
Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology
fiercebiotech.com
-
Listen to what our clients and candidates have said about us... An amazing testimonial for Thomas White, Senior Associate here at Mantell Associates! "I’m writing this note to recommend Mantell Associates and Thomas White, in particular, to those in search of a new position. I found the process of working with Tom to be extremely efficient, particularly considering that we had an eight hour time difference between us. We had focused yet detailed discussions ensuring that he understood what I was looking for, and that it was clear to me the specifics of the positions that he presented. I found Tom to be very patient, professional, and dedicated to a successful outcome for us both. As I said, I’m very happy to recommend Tom." Contact Thomas on +44 (0)20 3854 7700. #experience #recruitment #testimonialtuesday
-
-
Otsuka Pharmaceutical Co., Ltd. entered into a definitive merger agreement to acquire Jnana Therapeutics, for $800 million, as well as up to an additional $325 million in development and regulatory milestones. Read more below: https://lnkd.in/euNzksy5 #acquisition #drugdiscovery #pharmanews
Otsuka Pharmaceutical to Acquire Jnana Therapeutics for $800M
contractpharma.com
-
A huge thank you to Tiaan Marufu as she celebrates one year at Mantell Associates! Tiaan joined the team in August 2023 and has since become an integral member of our London office and global team. Tiaan specialises in all things Regulatory and Quality across Europe and the US, and has really made that space her own. Congratulations on your one year anniversary and we all look forward to seeing you flourish! #workanniversary #team #thankyou
-
-
Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma. Read more below: https://lnkd.in/ekxia_YV #celltherapy #solidtumour #cellandgene
FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor
fiercepharma.com